Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • XDx Inc sales and marketing update

    XDx Inc., Brisbane, Calif. Business: Diagnostic XDx said health insurer Cigna Corp. (NYSE:CI, Bloomfield, Conn.) issued a positive coverage decision for XDx's AlloMap Molecular Expression Test for patients from six …

    Published on 4/7/2014
  • Ambry Genetics sales and marketing update

    Ambry Genetics Corp., Aliso Viejo, Calif. Business: Diagnostic Ambry launched the ExomeNext and ExomeNext-Rapid assays for exome sequencing in a clinical setting. ExomeNext has a list price of $5,800 and provides …

    Published on 3/31/2014
  • AstraZeneca sales and marketing update

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Gastrointestinal AstraZeneca launched Nexium Direct, a program that provides U.S. patients the option to order Nexium esomeprazole to treat gastroesophageal …

    Published on 3/31/2014
  • BioDelivery, Quintiles, Ashfield Market Access LLC sales and marketing update

    BioDelivery Sciences International Inc. (NASDAQ:BDSI), Raleigh, N.C. Quintiles Transnational Holdings Inc. (NYSE:Q), Research Triangle Park, N.C. Ashfield Market Access LLC, Durham, N.C. Business: Neurology Quintiles …

    Published on 3/31/2014
  • Biohit sales and marketing update

    Biohit Oyj (HSE:BIOBV), Helsinki, Finland Business: Diagnostic Biohit launched its Calprotectin test in Europe, the Middle East and Asia for early detection and monitoring of inflammatory bowel disease (IBD), such as …

    Published on 3/31/2014
  • Cardiome, Vianex S.A. sales and marketing update

    Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME), Vancouver, B.C. Vianex S.A., Erythrea, Greece Business: Cardiovascular Cardiome's Cardiome International A.G. subsidiary granted Vianex rights to commercialize IV Brinavess …

    Published on 3/31/2014
  • CSL sales and marketing update

    CSL Ltd. (ASX:CSL), Melbourne, Australia Business: Hematology CSL's CSL Behring subsidiary launched the My Access cost share program, which covers up to $12,000 in annual out-of-pocket costs of a CSL Behring therapy for…

    Published on 3/31/2014
  • GlaxoSmithKline, Merck, U.S. Centers for Medicare & Medicaid Services (CMS), U.S. Food and Drug Administration (FDA) sales and marketing update

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. U.S. Centers for Medicare & Medicaid Services (CMS), Baltimore, Md. U.S. Food and Drug Administration (FDA), …

    Published on 3/31/2014
  • Grupo Ferrer International S.A., Medimetriks sales and marketing update

    Grupo Ferrer International S.A., Barcelona, Spain Medimetriks Pharmaceuticals Inc., Fairfield, N.J. Business: Infectious Ferrer granted Medimetriks exclusive commercialization rights to ozenoxacin 1% formulation in the …

    Published on 3/31/2014
  • Medline Industries Inc. sales and marketing update

    Medline Industries Inc., Mundelein, Ill. Business: Dermatology Medline launched Revitalon amniotic membrane allografts in the U.S. for wound covering. The Musculoskeletal Transplant Foundation (Edison, N.J.) procures …

    Published on 3/31/2014
  • Merz sales and marketing update

    Merz GmbH & Co. KGaA, Frankfurt, Germany Business: Neurology Merz's U.S. subsidiary Merz Pharmaceuticals LLC will launch on April 1 the My Merz Select physician loyalty program for its aesthetic products. Merz markets …

    Published on 3/31/2014
  • NovaMedica, SIFI S.p.A. sales and marketing update

    NovaMedica LLC, Moscow, Russia SIFI S.p.A., Aci S. Antonio, Italy Business: Ophthalmic SIFI granted NovaMedica exclusive rights to commercialize eight ophthalmic products in the Commonwealth of Independent States (CIS).…

    Published on 3/31/2014
  • Otsuka Pharmaceutical, Takeda sales and marketing update

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Gastrointestinal The pharmas partnered to co-promote Takeda's TAK-438 in Japan. Otsuka will pay Takeda 20 …

    Published on 3/31/2014
  • Aerocrine sales and marketing update

    Aerocrine AB (SSE:AERO), Solna, Sweden Business: Diagnostic Aerocrine said that Health Care Service Corp. (HCSC) will add coverage of fractional exhaled nitric oxide (FeNO) testing, effective April 1. HCSC provides …

    Published on 3/24/2014
  • Azano, Manhattan Scientifics sales and marketing update

    Azano Pharmaceuticals Inc., Albuquerque, N.M. Manhattan Scientifics Inc. (OTCQB:MHTX), New York, N.Y. Business: Diagnostic Manhattan Scientifics granted Azano exclusive, worldwide rights to commercialize NanoMRX …

    Published on 3/24/2014
  • BioAlliance, Innocutis sales and marketing update

    BioAlliance Pharma S.A. (Euronext:BIO), Paris, France Innocutis Holdings LLC, Charleston, S.C. Business: Infectious BioAlliance granted Innocutis exclusive commercialization rights in North America for Sitavig acyclovir…

    Published on 3/24/2014
  • Cardiome, Logista Pharma sales and marketing update

    Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME), Vancouver, B.C. Logista Pharma S.A., Madrid, Spain Business: Cardiovascular Cardiome granted Logista rights to commercialize IV Brinavess vernakalant in Spain. Cardiome said…

    Published on 3/24/2014
  • Gilead sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Starting next half, Gilead will provide HCV drug Sovaldi sofosbuvir in Egypt at $300 for a four-week supply - or $900 for a 12-week course of …

    Published on 3/24/2014
  • Good Start Genetics, PerkinElmer sales and marketing update

    Good Start Genetics Inc., Cambridge, Mass. PerkinElmer Inc. (NYSE:PKI), Waltham, Mass. Business: Diagnostic Good Start granted PerkinElmer exclusive rights to market the GoodStart Select carrier screening tests to …

    Published on 3/24/2014
  • Lundbeck, Otsuka Pharmaceutical sales and marketing update

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: Neurology H. Lundbeck and Otsuka launched once-monthly, intramuscular Abilify Maintena aripiprazole in Europe for …

    Published on 3/24/2014
  • Meda, Mission Pharmacal sales and marketing update

    Meda AB (SSE:MEDAA), Solna, Sweden Mission Pharmacal Co., San Antonio, Texas Business: Genitourinary Mission Pharmacal received rights to promote Meda's Elestrin estradiol gel in the U.S. The bioidentical estradiol …

    Published on 3/24/2014
  • NeoGenomics sales and marketing update

    NeoGenomics Inc. (NASDAQ:NEO), Fort Myers, Fla. Business: Pharmacogenetics NeoGenomics launched two next-generation sequencing cancer profiling tests. The myelodysplastic syndrome (MDS) test covers 16 genes and can be …

    Published on 3/24/2014
  • Novartis sales and marketing update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Ophthalmic Novartis launched the Lucentis ranibizumab pre-filled syringe in Germany, with other markets to follow this year. The syringe, which is designed …

    Published on 3/24/2014
  • Qiagen sales and marketing update

    Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN), Venlo, the Netherlands Business: Diagnostic Qiagen launched QuantiFeron-TB Gold In-Tube blood test in China to diagnose Mycobacterium tuberculosis infection. The test was approved …

    Published on 3/24/2014
  • Quinnova sales and marketing update

    Quinnova Pharmaceuticals LLC, Jamison, Pa. Business: Dermatology Quinnova launched Ecoza econazole nitrate topical foam in the U.S. to treat interdigital tinea pedis in patients ages 12 years and older. Ecoza is a …

    Published on 3/24/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993